## Jean-Pierre Gerard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3640642/publications.pdf

Version: 2024-02-01

51 papers	6,855 citations	29 h-index	197818 49 g-index
52	52	52	5366
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Propensity score analysis of radical proctectomy versus organ preservation using contact X-ray brachytherapy for rectal cancer. Clinical and Translational Radiation Oncology, 2022, 33, 70-76.	1.7	2
2	GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer. Clinical and Translational Radiation Oncology, 2022, 33, 15-22.	1.7	12
3	Targeted Radiotherapy Using Contact X-ray Brachytherapy 50 kV. Cancers, 2022, 14, 1313.	3.7	3
4	Contact x-ray brachytherapy (Papillon) in addition to chemoradiotherapy to improve organ preservation in early cT2-T3 rectal adenocarcinoma: The 3-year results of OPERA randomized trial (NCT02505750) Journal of Clinical Oncology, 2022, 40, 3512-3512.	1.6	18
5	International validation of the Immunoscore-biopsy (IS <sub>B</sub> ) to guide selection and monitoring of patients treated with watch-and-wait (WW) strategy for rectal cancer Journal of Clinical Oncology, 2022, 40, 3517-3517.	1.6	2
6	Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiotherapy and Oncology, 2021, 154, 154-160.	0.6	45
7	Does non-TME surgery of rectal cancer compromise the chance of cure? Preliminary surgical salvage data from OPERA phase III randomized trial Journal of Clinical Oncology, 2021, 39, 12-12.	1.6	10
8	Contact X-ray brachytherapy for rectal cancer: Past, present, and future. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 795-800.	1.4	7
9	A multi-centre analysis of adjuvant contact X-ray brachytherapy (CXB) in rectal cancer patients treated with local excision – Preliminary results of the CONTEM1 study. Radiotherapy and Oncology, 2021, 162, 195-201.	0.6	13
10	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nature Reviews Clinical Oncology, 2021, 18, 805-816.	27.6	93
11	Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence. Clinical and Translational Radiation Oncology, 2020, 24, 92-98.	1.7	6
12	A brief history of contact X-ray brachytherapy 50ÂkVp. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 222-225.	1.4	10
13	Impact of singleâ€nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORDâ€12/PRODIGEâ€2 phase III trial. International Journal of Cancer, 2019, 145, 3163-3172.	5.1	11
14	Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study. European Journal of Cancer, 2019, $108$ , $1-16$ .	2.8	49
15	A systematic review comparing radiation toxicity after various endorectal techniques. Brachytherapy, 2019, 18, 71-86.e5.	0.5	10
16	Organ preservation for T2-T3 rectal cancer: opportunistic or planned strategy. Oncotarget, 2019, 10, 3431-3432.	1.8	3
17	Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal. Journal of Contemporary Brachytherapy, 2018, 10, 522-531.	0.9	4
18	Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Samp; Wait Database (IWWD): an international multicentre registry study. Lancet, The, 2018, 391, 2537-2545.	13.7	677

#	Article	IF	CITATIONS
19	Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. European Journal of Surgical Oncology, 2018, 44, 1685-1702.	1.0	100
20	Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Digestive and Liver Disease, 2017, 49, 359-367.	0.9	65
21	Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients. European Journal of Cancer, 2017, 72, 124-136.	2.8	36
22	Immunotherapy for rectal carcinoma: Some stimulating data but still a long way to clinical evidence. European Journal of Cancer, 2016, 68, 70-72.	2.8	0
23	Pathologic Response, When Increased by Longer Interval, Is a Marker but Not the Cause ofÂGood Prognosis in Rectal Cancer: 17-year Follow-up of the Lyon R90-01 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2016, 94, 544-553.	0.8	50
24	New Neoadjuvant Treatment Strategies for Non-Metastatic Rectal Cancer (M0). Current Colorectal Cancer Reports, 2015, 11, 289-297.	0.5	0
25	Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud $\hat{a} \in \mathbb{C}^*$ Nice experience using contact x-ray brachytherapy and external beam radiotherapy for 120 patients. Acta Oncol $\tilde{A}^3$ gica, 2015, 54, 550-556.	1.8	30
26	Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiotherapy and Oncology, 2015, 115, 246-252.	0.6	53
27	Interstitial high-dose rate brachytherapy as boost for anal canal cancer. Radiation Oncology, 2014, 9, 240.	2.7	22
28	Results of age-dependent anal canal cancer treatment: A single centre retrospective study. Digestive and Liver Disease, 2014, 46, 460-464.	0.9	14
29	Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: Tolerance and efficacy. Radiotherapy and Oncology, 2014, 110, 144-149.	0.6	43
30	Past, present, and future of radiotherapy for the benefit of patients. Nature Reviews Clinical Oncology, 2013, 10, 52-60.	27.6	289
31	Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer. Journal of Clinical Oncology, 2012, 30, 4558-4565.	1.6	360
32	Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial. Journal of Clinical Oncology, 2012, 30, 1941-1948.	1.6	305
33	Towards a "Lyon molecular signature―to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94Ârectal cancers T1-2-3 Nx MO to be the basis of a molecular signature. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2012, 16. 688-696.	1.4	2
34	Clinical outcome of rectal cancer in patients ≥ 80Âyears treated in southern France (PACA region) between 2002 and 2005. Strahlentherapie Und Onkologie, 2012, 188, 383-387.	2.0	5
35	Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: Lessons from a systematic review of recent randomized trials. Critical Reviews in Oncology/Hematology, 2012, 81, 21-28.	4.4	59
36	Contact radiotherapy using a 50kV X-ray system: Evaluation of relative dose distribution with the Monte Carlo code PENELOPE and comparison with measurements. Radiation Physics and Chemistry, 2012, 81, 609-617.	2.8	32

#	Article	IF	CITATIONS
37	Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials. Journal of Clinical Oncology, 2011, 29, 3163-3172.	1.6	439
38	Renaissance of contact x-ray therapy for treating rectal cancer. Expert Review of Medical Devices, 2011, 8, 483-492.	2.8	38
39	Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2. Journal of Clinical Oncology, 2010, 28, 1638-1644.	1.6	686
40	Contact X-ray Therapy for Rectal Cancer: Experience in Centre Antoine-Lacassagne, Nice, 2002–2006. International Journal of Radiation Oncology Biology Physics, 2008, 72, 665-670.	0.8	41
41	Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: A retrospective study. Radiotherapy and Oncology, 2006, 79, 75-79.	0.6	29
42	Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203. Journal of Clinical Oncology, 2006, 24, 4620-4625.	1.6	1,551
43	Improved Sphincter Preservation in Low Rectal Cancer With High-Dose Preoperative Radiotherapy: The Lyon R96-02 Randomized Trial. Journal of Clinical Oncology, 2004, 22, 2404-2409.	1.6	306
44	Radiotherapy alone in the curative treatment of rectal carcinoma. Lancet Oncology, The, 2003, 4, 158-166.	10.7	66
45	Long-term control of T2–T3 rectal adenocarcinoma with radiotherapy alone. International Journal of Radiation Oncology Biology Physics, 2002, 54, 142-149.	0.8	92
46	Management of inguinal lymph node metastases in patients with carcinoma of the anal canal. Cancer, 2001, 92, 77-84.	4.1	153
47	Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group. Radiotherapy and Oncology, 1999, 51, 129-131.	0.6	39
48	Influence of the Interval Between Preoperative Radiation Therapy and Surgery on Downstaging and on the Rate of Sphincter-Sparing Surgery for Rectal Cancer: The Lyon R90-01 Randomized Trial. Journal of Clinical Oncology, 1999, 17, 2396-2396.	1.6	719
49	Endocavitary irradiation for early rectal carcinomas T1 (T2). A series of 101 patients treated with the Papillon's technique. International Journal of Radiation Oncology Biology Physics, 1996, 34, 775-783.	0.8	82
50	Radiation therapy in the conservative treatment of carcinoma of the anal canal. International Journal of Radiation Oncology Biology Physics, 1994, 29, 17-23.	0.8	71
51	Interstitial curietherapy in the conservative treatment of anal and rectal cancers. International Journal of Radiation Oncology Biology Physics, 1989, 17, 1161-1169.	0.8	103